Population
In vitro model using purified Ca-ATPase co-reconstituted with Phospholamban and its mutants
Comparison
PLB mutants (C41L-PLB and L37A-PLB) vs Wild type-PLB (wt-PLB)
Design
Preclinical
Authors
Loading...
Monomer potency of PLB may inform SERCA-targeted HF strategies; leaves open validation in human myocardium.
The inhibition of Ca-ATPase by Phospholamban depends on both its dissociation into monomers and the specific potency of the resulting monomer.
Reddy et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: